User login
Key clinical point: Combination of dupilumab and topical corticosteroids (TCS) improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomic regions in adults with moderate-to-severe AD.
Major finding: Dupilumab+TCS vs. placebo+TCS significantly improved infiltration/papulation score in head and neck, trunk, and upper extremities; excoriation score in trunk, upper, and lower extremities; lichenification score in trunk by week 2; and erythema score in head and neck and trunk by week 4 (all P ≤ .001), with all improvements sustained until week 52 (P ≤ .001).
Study details: Findings are post hoc analysis of 52-week phase 3 LIBERTY AD CHRONOS trial including 421 patients with moderate-to-severe AD who were randomly assigned to receive dupilumab+TCS or placebo+TCS.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. Some of the authors declared receiving grants and personal fees or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.
Source: Blauvelt A et al. Dermatol Ther (Heidelb). 2021 (Nov 22). Doi: 10.1007/s13555-021-00638-1.
Key clinical point: Combination of dupilumab and topical corticosteroids (TCS) improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomic regions in adults with moderate-to-severe AD.
Major finding: Dupilumab+TCS vs. placebo+TCS significantly improved infiltration/papulation score in head and neck, trunk, and upper extremities; excoriation score in trunk, upper, and lower extremities; lichenification score in trunk by week 2; and erythema score in head and neck and trunk by week 4 (all P ≤ .001), with all improvements sustained until week 52 (P ≤ .001).
Study details: Findings are post hoc analysis of 52-week phase 3 LIBERTY AD CHRONOS trial including 421 patients with moderate-to-severe AD who were randomly assigned to receive dupilumab+TCS or placebo+TCS.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. Some of the authors declared receiving grants and personal fees or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.
Source: Blauvelt A et al. Dermatol Ther (Heidelb). 2021 (Nov 22). Doi: 10.1007/s13555-021-00638-1.
Key clinical point: Combination of dupilumab and topical corticosteroids (TCS) improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomic regions in adults with moderate-to-severe AD.
Major finding: Dupilumab+TCS vs. placebo+TCS significantly improved infiltration/papulation score in head and neck, trunk, and upper extremities; excoriation score in trunk, upper, and lower extremities; lichenification score in trunk by week 2; and erythema score in head and neck and trunk by week 4 (all P ≤ .001), with all improvements sustained until week 52 (P ≤ .001).
Study details: Findings are post hoc analysis of 52-week phase 3 LIBERTY AD CHRONOS trial including 421 patients with moderate-to-severe AD who were randomly assigned to receive dupilumab+TCS or placebo+TCS.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. Some of the authors declared receiving grants and personal fees or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.
Source: Blauvelt A et al. Dermatol Ther (Heidelb). 2021 (Nov 22). Doi: 10.1007/s13555-021-00638-1.